Kei Yamada

Kei Yamada

Auto-generated profile, based on publicly available information

Kei Yamada

Chemical Biology and Therapeutics Science Broad Institute of MIT and Harvard Cambridge MA 02142 USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2019 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
KYKei Yamada
Kei Yamada
NSNatsuki Shikida
Natsuki Shikida
KSKazutaka Shimbo
Kazutaka Shimbo
YIYuji Ito
Yuji Ito
ZKZahra Khedri
Zahra Khedri
BMBrian Mendelsohn
Brian Mendelsohn


27 September 2021 in Molecular Pharmaceutics
Verified
Journal Article
Open access
YMYutaka Matsuda
Yutaka Matsuda
TSTakuya Seki
Takuya Seki
KYKei Yamada
Kei Yamada
YOYuri Ooba
Yuri Ooba
KTKazutoshi Takahashi
Kazutoshi Takahashi
TOTatsuya Okuzumi
Tatsuya Okuzumi
To overcome a lack of selectivity during the chemical modification of native non-engineered antibodies, we have developed a technology platform termed “AJICAP” for the site-specific chemical conjugation of antibodies through the use of a class of IgG Fc-affinity reagents. To date, a limited number of antibody–drug conjugates (ADCs) have been synthesized via this approach, and no toxicological study was reported. Herein, we describe the compatibility and robustness of AJICAP technology, which enabled the synthesis of a wide variety of ADCs. A stability assessment of a thiol-modified antibody synthesized by AJICAP technology indicated no appreciable increase in aggregation or decomposition upon prolonged storage, indicating that the unexpectedly stable thiol intermediate has a great potential intermediate for payload or linker screening or large-scale manufacturing. Payload conjugation with this stable thiol intermediate generated several AJICAP-ADCs. In vivo xenograft studies indicated that the AJICAP-ADCs displayed significant tumor inhibition comparable to benchmark ADC Kadcyla. Furthermore, a rat pharmacokinetic analysis and toxicology study indicated an increase in the maximum tolerated dose, demonstrating an expansion of the AJICAP-ADC therapeutic index, compared with stochastic conjugation technology. This is the first report of the therapeutic index estimation of site-specific ADCs produced by utilizing Fc affinity reagent conjugation. The described site-specific conjugation technology is a powerful platform to enable next-generation ADCs through reduced heterogeneity and enhanced therapeutic index.

8 October 2014 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
KYKei Yamada
Kei Yamada
MLMartin Lear
Martin Lear
TYTakaya Yamaguchi
Takaya Yamaguchi
SYShuji Yamashita
Shuji Yamashita
IGIlya D. Gridnev
Ilya D. Gridnev
MHMasahiro Hirama
Masahiro Hirama

5 December 2019 in Organic Process Research & Development
Verified
Journal Article
Closed access
YMYutaka Matsuda
Yutaka Matsuda
KYKei Yamada
Kei Yamada
TOTatsuya Okuzumi
Tatsuya Okuzumi
BMBrian Mendelsohn
Brian Mendelsohn

7 April 2021 in Spine
Verified
Journal Article
Closed access
MTMasahito Takahashi
Masahito Takahashi
SIShiro Imagama
Shiro Imagama
KKKazuyoshi Kobayashi
Kazuyoshi Kobayashi
KYKei Yamada
Kei Yamada
GYGo Yoshida
Go Yoshida
YMYukihiro Matsuyama
Yukihiro Matsuyama
Study Design.: Prospective multicenter cohort study. Objective.: The aim of this study was to validate an alarm point of intraoperative neurophysiological monitoring () formulated by the Monitoring Working Group (WG) of the Japanese Society for Spine Surgery and Related Research (JSSR). Summary of Background Data.: The Monitoring WG of the JSSR formulated an alarm point of IONM using transcranial electrical stimulation-muscle motor evoked potentials (Tc(E)-MEPs) and has conducted a prospective multicenter study. The validity of the JSSR alarm point of ≥ 70% decreased in Tc(E)-MEPs for each high-risk surgery and any other spine surgeries has not been verified. Methods.: Patients who underwent spine and spinal cord surgery with IONM in 16 Japanese spine centers in the Monitoring WG of the JSSR from 2017 to 2018 were enrolled. The patients were divided into the high-risk surgery group (Group HR) and the common surgery group (Group C). Group HR was defined by ossification of the posterior longitudinal ligament (OPLL), spinal deformity, and spinal cord tumor. Group C was classified as other spine surgeries. The alarm point was defined as a ≥70% decrease in the Tc(E)-MEPs. Results.: In Group HR, the sensitivity and specificity were 94.4% and 87.0%, respectively. In Group C, the sensitivity and specificity were 63.6% and 91.9%. The sensitivity in Group C was statistically lower than that in Group HR (P < 0.05). In Group HR, the sensitivity and specificity in OPLL were 100% and 86.9%, respectively. The sensitivity and specificity in spinal deformity were 87.5% and 84.8%, respectively, and the sensitivity and specificity in spinal cord tumors were 92.9% and 89.9%, respectively. The sensitivity and specificity in each high-risk surgery showed no significant difference. Conclusion.: The alarm point of IONM by the Monitoring WG of the JSSR appeared to be valid for each disease in Group HR. Meanwhile, applying the JSSR alarm point for Group C potentially needed attention. Level of Evidence: 3